Clinical trial
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage…
NCT00006113 · University of Southern California, Other · Terminated
Key facts
| NCT number | NCT00006113 |
|---|---|
| Title | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | A Phase II Trial of a MART-1/gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Treated With CD40 Ligand/Gamma Interferon With Subcutaneous IL-2 for Patients With Metastatic Melanoma |
| Lead sponsor | University of Southern California, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Radiation |
| Interventions | MART-1 antigen, aldesleukin, gp100 antigen, recombinant CD40-ligand, recombinant interferon gamma, recombinant interleukin-4, sargramostim, therapeutic autologous dendritic cells, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide and 1 more |
| Enrollment | 25 |
| Start date | Jun 1, 1999 |
| Primary completion | May 1, 2003 |
| Completion | Apr 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: